Skip to main content
TOVX
NASDAQ Life Sciences

Theriva Sells Ribaxamase Portfolio to Biossil for $350K Upfront, Up to $91M in Milestones

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Neutral
Importance info
8
Price
$0.18
Mkt Cap
$8.724M
52W Low
$0.136
52W High
$0.492
52W Position info
32% above low
Off High info
63% below high
Rel. Volume info
45× avg
Market data snapshot near publication time

TOVX sits 32% above its 52-week low of $0.136 on elevated volume (45× avg).

Summary

Theriva sold SYN-004 (ribaxamase), SYN-007 and certain SYN-006 assets to Biossil Labs for a $350,000 upfront payment, with up to $91 million in contingent regulatory and sales milestones plus a capped royalty. Biossil takes over all future development costs, leaving Theriva with VCN-01 as its lead program.


Key Events · M&A and Partnerships · TOVX

  • Ribaxamase Portfolio Sold to Biossil

    Theriva sold all rights to SYN-004 (ribaxamase), SYN-007 and certain SYN-006 assets to Toronto-based Biossil Labs Inc., with closing concurrent with the October 30, 2026 signing.

  • $350K Upfront, Up to $91M Contingent

    Biossil paid $350,000 non-refundable at closing; Theriva may receive up to $3 million on first FDA approval and first EMA marketing authorization plus up to $88 million on cumulative worldwide net sales thresholds.

  • Royalty Capped at $250 Million

    A low-single-digit royalty on worldwide net sales of the transferred products is capped at $250 million in aggregate, plus a low-double-digit share of license consideration that sits outside the cap.

  • PREV ABR Takes Half of Milestones

    An amendment to the 2012 PREV ABR agreement requires a $140,000 closing payment and then 50% of milestone payments, 33⅓% of royalties and 50% of other consideration, capped at $13.0 million in aggregate.


Analysis · TOVX · Life Sciences

Theriva has exited its antibiotic-degrading enzyme franchise entirely, handing development and cost burden to Biossil in exchange for $350,000 cash at closing plus contingent milestones and royalties. Against a roughly $8.7 million market value, the near-term cash is negligible — the real question is whether Biossil can push a paused Phase 1b/2a program and an unapproved asset to market, which is what the up to $3 million regulatory and up to $88 million sales milestones depend on. The filing explicitly warns there is no assurance any milestone will be achieved. Theriva also gave up half of milestone proceeds, a third of royalties and half of other consideration to PREV ABR under a $13.0 million cap, further thinning the economics. What remains is VCN-01, the oncolytic adenovirus, now the lead asset with no partnered revenue behind it.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, TOVX was trading at $0.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.7M. The 52-week trading range was $0.14 to $0.49. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

TOVX - Latest Insights

TOVX
Nov 18, 2026, 4:31 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.144
Real-time Price: $0.135 info
Change: -$0.0090 (-6%) info
Market Cap: $5.874M info
TOVX
Nov 12, 2026, 8:15 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.160
Real-time Price: $0.135 info
Change: -$0.025 (-16%) info
Market Cap: $5.874M info
TOVX
Nov 12, 2026, 8:10 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.160
Real-time Price: $0.135 info
Change: -$0.025 (-16%) info
Market Cap: $5.874M info